References
- Chisesi T, Capnist G, de Dominicis E, Dini E. A phase II study of idarubicin (4‐demethoxydaunorubicin) in advanced myeloma. Eur J Cancer Clin Oncol 1988; 24: 681–4
- Alberts A S, Falkson G, Rapoport B L, Uys A. A phase II study of idarubicin and prednisone in multiple myeloma. Tumori 1990; 76: 465–6, Samson D, Oral idarubicin with CCNU (lomustine) and dexatnethasone in the treatment of refractory or relapsed multiple myeloma, Research and Clinical Forums 1996, 18(3): 87–93
- Cook G, Sharp R A, Tansey P, Franklin I M. A phase I/II trial of Z‐dex) oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Brit J Haematol 1996; 93: 9314
- Samson D. Oral idarubicin with CCNU (lomustine) and dexamethasone in the treatment of refractory or relapsed multiple myeloma. Research and Clinical Forums 1996; 18(3)87–93
- Samson D, Gaminara E, Newland A, Van de Pette J, Kearney J, McCarthy D, Joyner M, Aston L, Mitchell T, Hamon M, Barrett A J, Evans M. Infusion of vincristine and doxorubicin with oral dexamethasone as first‐line therapy for multiple myeloma. Lancet 1989; 2: 882–5